CN101721467B - Method for preparing total salvianolic acid - Google Patents
Method for preparing total salvianolic acid Download PDFInfo
- Publication number
- CN101721467B CN101721467B CN 200810152400 CN200810152400A CN101721467B CN 101721467 B CN101721467 B CN 101721467B CN 200810152400 CN200810152400 CN 200810152400 CN 200810152400 A CN200810152400 A CN 200810152400A CN 101721467 B CN101721467 B CN 101721467B
- Authority
- CN
- China
- Prior art keywords
- lower alcohol
- radix salviae
- salviae miltiorrhizae
- total phenolic
- salvianolic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a method for preparing total salvianolic acid. The method comprises the following steps of extracting Salvia miltiorrhiza by water-containing low-grade alcohol and extracting headspace polyamide or separating macroporous resin. The method has the advantages that the transferring rate of salvianolic acid B is high and can achieve 50-60%; the loss of active ingredients is low, the quality of the prepared product is good, the content of the total phenolic acid is equal to or greater than 80%, the content of salvianolic acid B is equal to or greater than 50%, and the therapeutic effect is obvious. The invention also discloses a preparation on pharmacy and a preparing purpose thereof.
Description
Technical field
The present invention relates to the field of Chinese medicines, be specifically related to a kind of method for preparing salvianolic acids.
Background technology
Radix Salviae Miltiorrhizae is the dry rhizome of labiate Radix Salviae Miltiorrhizae Salvia miltiorrhiza Bunge, be to use in China's traditional medicine the earliest and one of medicine the most widely, clinical practice and modern medicine study through long-term have had comprehensive understanding to its clinical effectiveness, pharmacological action.Traditional Chinese medicine theory thinks that Radix Salviae Miltiorrhizae can blood circulation promoting and blood stasis dispelling; Menstruction regulating and pain relieving; Nourishing blood to tranquillize the mind; The removing heat from blood eliminating carbuncle cures mainly menoxenia; Dysmenorrhea; Amenorrhea; The stasis of blood stagnated and suffered from abdominal pain puerperal; Trusted subordinate's pain; Lumps in the chest and abdomen; Pyretic arthralgia swells and ache; Traumatic injury; Heat is gone into nutrient blood; Dysphoria; Vexed insomnia; The carbuncle pyogenic infections from tumour or sore.Modern pharmacology studies show that; effects such as Radix Salviae Miltiorrhizae has cerebral ischemia protection, improve coronary flow and microcirculation, promotion tissue repair, antiplatelet aggregation, antitumor, antiinflammatory are antibacterial are mainly used in diseases such as coronary heart disease coronary heart disease, acute myocardial infarction, cerebral infarction, chronic hepatitis clinically.Recent study finds that also Radix Salviae Miltiorrhizae also has certain curative effect to diseases such as insomnia, chronic hepatitis, tumor and digestive tract ulcer.(Chinese patent, application number 200710111232.4, applying date 2007.6.18).
Effective ingredient in the Radix Salviae Miltiorrhizae comprises liposoluble constituent and water soluble ingredient.Liposoluble constituent is to be the quinones of representative with the TANSHINONES, has good antiinflammatory action; Water-soluble components mainly contains danshensu, protocatechualdehyde, rosmarinic acid, alkannic acid, caffeic acid, salvianolic acid (A, B), is generically and collectively referred to as total phenolic acid, also has report to be called salvianolate or poly phenolic acid of Radix Salviae Miltiorrhizae.Radix Salviae Miltiorrhizae total phenolic acids has effects such as tangible antithrombotic formation, molten fibre and anti peroxidation of lipid, is the effective ingredient of cardiovascular disease such as treatment myocardial ischemia, angina pectoris, myocardial infarction, and wherein the content of salvianolic acid B is the highest, and is its main active component.(separation purifying technique of total phenolic acid research in the Radix Salviae Miltiorrhizae, Yang Xiaoning etc., Chinese herbal medicine, 2007,38 (6): 843-846).
The extracting method of Radix Salviae Miltiorrhizae total phenolic acids mostly is uses water extraction, reuse ethanol precipitation, the method for purification by macroporous resin earlier, precipitate with ethanol efficient is low, loss big (Wang Zhi equality, the resin absorption of Radix Salviae Miltiorrhizae extract and alcohol precipitation process comparative study, ion exchange and absorption, 2003,19 (6): 554-560).Poplar Xiao Ning etc. optimize original aqueous extraction-alcohol precipitation technology and improve, but the poor stability because of salvianolic acid, the rate of transform of water extraction salvianolic acid B is low, and the content of total phenolic acid and salvianolic acid B is all lower, be respectively 51.62% and 30.97% (separation purifying technique of total phenolic acid research in the Radix Salviae Miltiorrhizae, Yang Xiaoning etc., Chinese herbal medicine, 2007,38 (6): 843-846).
Summary of the invention
In order to address the above problem, the present invention provides a kind of preparing salvianolic acids on the basis that does not increase cost, adopts this method salvianolic acid B rate of transform height, in the product content height, the quality of total phenolic acid and salvianolic acid B good, be easy to industrialization.
Another object of the present invention provides the Radix Salviae Miltiorrhizae total phenolic acids that obtains with said method.
It is the pharmaceutical composition of active component that another purpose of the present invention provides with the Radix Salviae Miltiorrhizae total phenolic acids.
A further object of the present invention provides the application of Radix Salviae Miltiorrhizae total phenolic acids.
The present invention may further comprise the steps substantially:
(a) the moisture lower alcohol extraction of Radix Salviae Miltiorrhizae;
(b) polyamide or macroporous resin column are separated on the extracting solution.
The present invention further is achieved through the following technical solutions:
(1) Radix Salviae Miltiorrhizae is removed impurity, pulverizes or make decoction pieces, uses moisture lower alcohol extraction;
(2) polyamide column or macroporous resin column on step (1) the gained extracting solution are the moisture lower alcohol I flushing of 10-60% with weight percent concentration, and the reuse weight percent concentration is the moisture lower alcohol II eluting of 40-95%, collects eluent;
(3) eluent concentrates, and drying namely gets Radix Salviae Miltiorrhizae total phenolic acids.
In the step (1), lower alcohol is C
1～C
4Straight or branched saturated alkyl alcohol, comprise methanol (CH
3OH), ethanol (CH
3CH
2OH), normal propyl alcohol [CH
3(CH
2) OH], isopropyl alcohol [(CH
3)
2CHOH], CH
3(CH
2)
3OH, (CH
3)
2CH
2CHOH, CH
3CH
2CH (CH
3) OH, (CH3)
3COH; Particular methanol, ethanol, isopropyl alcohol; Further particular methanol, ethanol; Most preferred ethanol.Moisture lower alcohol weight percent concentration is 10～90%, is preferably 30～85%.
The method of extracting comprises the extracting method of this area routines such as reflux, extract,, decoction, dipping, percolation, counter-current extraction, but is not limited thereto.The concrete parameter of extracting, as extracting solution consumption, time, temperature etc., those skilled in the art can determine according to general knowledge and the prior art of this area, need not creative work.Relevant vocabulary of terms referring to (Chinese medicine extraction method progress, Zhao Mengchun etc., pig industry science, 2007,2,32-33).
Owing to may have colored foreign in the extracting solution, better, carrying out step (2) before, can be with eluent by ion exchange resin, to remove pigment.
In the step (2), step (1) extracts that resulting extracting solution can directly be gone up polyamide column or macroporous resin column is separated, and goes up polyamide column again after also can concentrating earlier or macroporous resin column is separated.The weight percent concentration of described moisture lower alcohol I is preferably 10-40%, most preferably is 20-35%; Moisture lower alcohol II weight percent concentration is preferably 40-95%, most preferably is 50-80%; For separation process together, moisture lower alcohol I concentration is less than moisture lower alcohol II.
Macroporous adsorbent resin described in the step (2) can be any one types such as nonpolar, low pole, middle polarity, faintly acid or alkalescence, as D101, D4020, HPD400, AB-8, S-8, HZ-806, ZTC-1 etc., the resin of preferred low pole or middle polarity, as AB-8, HPD400, D101, ZTC-1, styrene type most preferably is as AB-8 type resin; Described polyamide material is caprolactam (nylon-6).Parameter when adopting polyamide column or macroporous adsorptive resins to separate, as the blade diameter length ratio of applied sample amount, elution speed, post etc., those skilled in the art can determine according to general knowledge and the prior art of this area, need not creative work.
The Radix Salviae Miltiorrhizae total phenolic acids that makes according to the inventive method can add acceptable accessories and make said pharmaceutical composition on any pharmaceutics as active constituents of medicine, also can add other drug and make compound formulation together.
Pharmaceutical composition of the present invention is the pharmaceutical dosage forms of unit dose, and described unit dosage form refers to the unit of preparation, as every of tablet, and every capsules of capsule, every bottle of oral liquid, every bag of granule etc.
Compositions of the present invention active component wherein, its shared percentage by weight in preparation can be 0.1-99.9%, all the other are the medicine acceptable carrier.
Compositions of the present invention obtains by above-mentioned active component and medicine acceptable carrier are mixed with.
Compositions of the present invention, its pharmaceutical dosage forms can be any pharmaceutically useful dosage form, and these dosage forms comprise: tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, suck agent, granule, electuary, pill, powder, unguentum, sublimed preparation, suspensoid, powder, solution, injection, suppository, ointment, plaster, cream, spray, drop, patch.Preparation of the present invention, peroral dosage form preferably, as: capsule, tablet, oral liquid, granule, pill, powder, sublimed preparation, unguentum etc.; And injection, as: injectable powder, injection, transfusion etc.
Compositions of the present invention, the preparation of its oral administration can contain excipient commonly used, such as binding agent, filler, diluent, tablet agent, lubricant, disintegrating agent, coloring agent, flavoring agent and wetting agent, can carry out coating to tablet in case of necessity.
The filler that is suitable for comprises cellulose, mannitol, lactose and other similar filler.Suitable disintegrating agent comprises starch, polyvinylpyrrolidone and starch derivatives, for example sodium starch glycollate.Suitable lubricant comprises, for example magnesium stearate.The acceptable wetting agent of appropriate drug comprises sodium lauryl sulphate.
Can fill by mixing, the method that tabletting etc. are commonly used prepares solid oral composition.Mix repeatedly active substance is distributed in those compositionss of a large amount of filleies of whole use.
The form of oral liquid for example can be aqueous or oily suspensions, solution, Emulsion, syrup or elixir, perhaps can be a kind of available water before use or other suitable composite dry products of carrier.This liquid preparation can contain conventional additive, such as suspending agent, for example sorbitol, syrup, methylcellulose, gelatin, hydroxyethyl-cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenation edible fat, emulsifying agent, for example lecithin, anhydro sorbitol monooleate or arabic gum; Non-aqueous carrier (they can comprise edible oil), for example almond oil, fractionated coconut oil, such as oily ester, propylene glycol or the ethanol of the ester of glycerol; Antiseptic, for example para hydroxybenzene methyl ester or propyl p-hydroxybenzoate or sorbic acid, and if desired, can contain conventional flavouring agent or coloring agent.
For injection, the liquid unit dosage forms of preparation contains active substance of the present invention and sterile carrier.According to carrier and concentration, this chemical compound can be suspended or dissolving.The preparation of solution is normally by being dissolved in active substance in a kind of carrier filter-sterilized before it is packed into a kind of suitable bottle or ampoule, sealing then.Adjuvant for example a kind of local anesthetic, antiseptic and buffer agent also can be dissolved in this carrier.In order to improve its stability, can be after the bottle of packing into that this compositions is freezing, and under vacuum, water is removed.
Compositions of the present invention, when being prepared into medicament, optionally add suitable medicine acceptable carrier, described medicine acceptable carrier is selected from: mannitol, sorbitol, sodium pyrosulfite, sodium sulfite, sodium thiosulfate, cysteine hydrochloride, TGA, methionine, vitamin C, the EDTA disodium, EDTA calcium sodium, the alkali-metal carbonate of monovalence, acetate, phosphate or its aqueous solution, hydrochloric acid, acetic acid, sulphuric acid, phosphoric acid, aminoacid, sodium chloride, potassium chloride, sodium lactate, xylitol, maltose, glucose, fructose, dextran, glycine, starch, sucrose, lactose, mannitol, silicon derivative, cellulose and derivant thereof, alginate, gelatin, polyvinylpyrrolidone, glycerol, soil temperature 80, agar, calcium carbonate, calcium bicarbonate, surfactant, Polyethylene Glycol, cyclodextrin, β-cyclodextrin, the phospholipid material, Kaolin, Pulvis Talci, calcium stearate, magnesium stearate etc.
Compositions of the present invention is determined usage and dosage according to patient's situation in use, but obeys every day three times, each 1-20 agent, as: 1-20 bag or grain or sheet.
Because Radix Salviae Miltiorrhizae total phenolic acids is the water soluble ingredient in the Radix Salviae Miltiorrhizae, so the traditional water extract-alcohol precipitation method of the many employings of those skilled in the art, loss of effective components is big.But because of the poor stability of salvianolic acid, the rate of transform of water extraction salvianolic acid B is low, and the highest only have 35%, and the impurity content height.The inventor adopts certain density moisture C by a large amount of discovering
1～C
4Lower alcohol extracts, and the rate of transform of salvianolic acid B obviously improves, and generally can reach 70～90% (adopting 75% methanol then up to more than 95%), and HPLC shows that the assorted peak of Radix Salviae Miltiorrhizae total phenolic acids in the extracting solution obviously reduces simultaneously.So adopt preparation method of the present invention, loss of effective components is few, the good product quality that obtains, total phenolic content 〉=80%, the content of salvianolic acid B 〉=50%, determined curative effect.Simultaneously because polyamide column chromatography and macroporous resin are separation means relatively more commonly used in producing, and product is effectively separated, so with respect to other separation methods, can not increase cost.
The Radix Salviae Miltiorrhizae total phenolic acids that adopts the inventive method to make, can be applicable to prepare the medicine for the treatment of following disease, i.e. cardiovascular and cerebrovascular disease, nephropathy, hepatopathy, pneumonia, pulmonary heart disease, pancreatitis, diabetes, cervical spondylosis, optical fundus blood vessel disease, optical fundus nervous system disease, migraine, chronic gastritis, dizzy, bone injury disease, high altitude disease, senile dementia etc.
The Radix Salviae Miltiorrhizae total phenolic acids for preparing with the method according to embodiment 3 is example below, investigates it to the improvement effect of the damage in learning and memory of ischemia-reperfusion mice and the influence of hypoxia-bearing capability.
The test example: salvianolic acid is to the improvement effect of the damage in learning and memory of ischemia-reperfusion mice and the influence of hypoxia-bearing capability.
Animal: Kunming mouse, ♂, body weight 23 ± 4g, totally 84, Chinese Academy of Medical Sciences experimental animal center provides.The quality certification: the moving word the 01-3008 of doctor
Experimental apparatus: mice diving tower experiment autographic apparatus, the Chinese Academy of Medical Sciences makes instrument electricity chamber.
Test method: mice is divided into seven groups at random: sham operated rats, matched group capacity normal saline such as () iv, FUFANG DANSHEN ZHUSHEYE group (iv Radix Salviae Miltiorrhizae Injection 50mg/kg respectively, 200mg/kg, 2g/kg), the salvianolic acid group (difference iv total salvianolic acid 3mg/kg, 6mg/kg, 10mg/kg), every group 12, (60mg/kg, ig) after the anesthesia, dorsal position is fixed with pentobarbital sodium.The neck median incision separates bilateral common carotid arteries, and wears with No. zero silk thread.Bilateral common carotid arteries blocking blood flow 10min recovers blood flow 10min then, triplicate like this, and skin suture, postoperative is normally raised by mice
[1]Sham operated rats is only separated bilateral common carotid arteries.10min behind the ischemia-reperfusion, the tail vein injection medicine, once a day, continuous three days.Carry out the diving tower experiment after second day administration half an hour
[2]Mice to be measured is put into the diving tower instrument, the 3min that conforms, then to the energising of bottom screen, the observation mice jumps onto the high platform time (response time) and the interior mice of 5min is jumped off the number of times (training period errors number) that is shocked by electricity by high platform.After 24 hours, mice is put on the high platform of experiment instrument, the bottom screen is switched on simultaneously, and the record mice jumps off in time (incubation period) of high platform and the 5min and is subjected to number of shocks (the phase errors number of resurveying).Ischemia-reperfusion mice group and medication are the same, adopt head-breaking to interrupt full brain blood supply fully, observe the full brain of mice and stop the mouth breathing persistent period after the blood supply.
Result of the test: The above results is represented with X ± S, relatively checks with t between group.
(1) protective effect of the mouse brain ischemical reperfusion injury of salvianolic acid iv
Step down test mainly is the influence of observing back 24 hours memory acquisition disturbances of training, response time and the errors number of training period are only for reference. show as table 1, compare with matched group, salvianolic acid 3mg/kg can reduce the response time (P＜0.05), prolong incubation period (P＜0.05), reduce the phase errors number (P＜0.01) of resurveying; Salvianolic acid 6mg/kg can prolong incubation period (P＜0.01), reduces the phase errors number (P＜0.01) of resurveying; Salvianolic acid 10mg/kg can reduce the response time (P＜0.001), prolongs incubation period (P＜0.01), reduces testing period and the phase errors number (being respectively P＜0.05, P＜0.01) of resurveying.FUFANG DANSHEN ZHUSHEYE 50mg/kg can reduce the response time (P＜0.05), reduce training period errors number (P＜0.05), FUFANG DANSHEN ZHUSHEYE 200mg/kg can prolong incubation period (P＜0.01), reduce training period and the phase errors number (P＜0.05, p＜0.01) of resurveying, FUFANG DANSHEN ZHUSHEYE 2g/kg can reduce the response time (P＜0.001), incubation period can be prolonged (P＜0.001), reduce training period and the phase errors number (being respectively p＜0.001, p＜0.01) of resurveying
The amnemonic protective effect that the mouse brain ischemical reperfusion injury of table 1 salvianolic acid and FUFANG DANSHEN ZHUSHEYE iv causes
* P＜0.05 * * P＜0.01 * * * P＜0.001VS. matched group
(2) influence of the hypoxia-bearing capability of the cerebral ischemia re-pouring mice of salvianolic acid iv
Show as table 2, compare with matched group that salvianolic acid 3mg/kg, 6mg/kg, 10mg/kg and FUFANG DANSHEN ZHUSHEYE 50mg/kg, 200mg/kg, 2g/kg all can significantly improve the hypoxia-bearing capability (p＜0.001) of cerebral ischemia re-pouring mice.
The influence of table 2 salvianolic acid and the cerebral ischemia re-pouring mice of FUFANG DANSHEN ZHUSHEYE iv hypoxia-bearing capability
* P＜0.05 * * * P＜0.001 VS. matched group
Conclusion (of pressure testing): salvianolic acid 3mg/kg, 6mg/kg, 10mg/kg can improve the learning and memory of cerebral ischemia re-pouring mice, significantly improves its hypoxia-bearing capability, and the effect of the effect of salvianolic acid 10mg/kg and FUFANG DANSHEN ZHUSHEYE 2g/kg is suitable.
The specific embodiment
The present invention is further illustrated below by concrete embodiment, but not as limitation of the present invention.
The detection method of Radix Salviae Miltiorrhizae total phenolic acids and salvianolic acid B: by the patent application document (Chinese patent, application number 01142288.2, the calendar year 2001 applying date JIUYUE) method measure.
(1) salvianolic acid B: measure with the HPLC method, detect wavelength 288nm, the standard substance salvianolic acid B provides purity 98.0% by sky, Tianjin Shi Li group modern Chinese medicine institute.
(2) Radix Salviae Miltiorrhizae total phenolic acids: content=F (A-B)+B
Wherein: A is that spectrophotometry is total phenolic content that contrast is calculated with the salvianolic acid B
B is the content of danshinolic acid B of high effective liquid chromatography for measuring
F is correction factor 0.626
Embodiment 1
Salvia piece 1000 grams, 10000ml60% alcohol reflux three times.Merge extractive liquid,, being concentrated into does not have alcohol, filters, and filtrate is by 500 gram polyamide columns, the flushing of 10000ml water, 95% ethanol 10000ml eluting, concentrate eluant, drying.Get extract 40 grams, content of danshinolic acid B 57%, Radix Salviae Miltiorrhizae total phenolic acids 86.6%.
Embodiment 2
Salvia piece 1000 grams, 6000m75% methanol extraction three times.Merge extractive liquid,, it is pure to be concentrated into nothing, filtration, filtrate is by 2000 gram AB-8 macroporous resins, and 15000ml water washes, and 80% ethanol elution is extremely complete, concentrate eluant, spray drying.Get extract 45 grams, content of danshinolic acid B 64%, Radix Salviae Miltiorrhizae total phenolic acids 93.4%.
Embodiment 3
Salvia piece 1000 grams, 15000m75% ethanol counter-current extraction.Merge extractive liquid,, being concentrated into does not have alcohol, filters, and filtrate is by 2000 gram D101 macroporous resin resins, 15000ml0% alcohol flushing, 50% ethanol 10000ml eluting, concentrate eluant, 60 degree vacuum dryings.Get extract 37 grams, content of danshinolic acid B 64%, Radix Salviae Miltiorrhizae total phenolic acids 89.5%.
Embodiment 4
Salvia piece 1000 grams, 15000m75% ethanol counter-current extraction.Merge extractive liquid,, being concentrated into does not have alcohol, filters, and filtrate is by 500 gram polyamide, 12000ml30% alcohol flushing, 95% ethanol 12000ml eluting, concentrate eluant, drying.Get extract 30 grams, content of danshinolic acid B 66%, Radix Salviae Miltiorrhizae total phenolic acids 96.5%.
Embodiment 5
Salvia piece 1000 grams, 6000m30% alcohol reflux three times.Merge extractive liquid, filters, and filtrate is by 500 gram polyamide columns, 12000ml50% alcohol flushing, 95% ethanol 12000ml eluting, collection eluent, concentrate eluant, drying.Get extract 45 grams, content of danshinolic acid B 58%, Radix Salviae Miltiorrhizae total phenolic acids 88.7%.
Embodiment 6 tablets
Prescription
Technology:
1 granulates
Other adjuvant is crossed 100 mesh sieves respectively in crude drug Radix Salviae Miltiorrhizae total phenolic acids extract and the prescription, take by weighing recipe quantity Radix Salviae Miltiorrhizae total phenolic acids extract and microcrystalline Cellulose, starch and carboxymethyl starch sodium and adopt the equivalent method mix homogeneously that progressively increases, with an amount of PVP ethanol solution soft material processed, 14 mesh sieves are granulated, 50～60 ℃ of dryings 1 hour, the magnesium stearate that adds recipe quantity is with 14 mesh sieve granulate.
2 tablettings
Get above-mentioned granule with the special-shaped punch die tabletting of special rhombus.
Embodiment 7 capsules
Prescription:
Technology:
1 granulates
Other adjuvant is crossed 100 mesh sieves respectively in crude drug Radix Salviae Miltiorrhizae total phenolic acids extract and the prescription, take by weighing recipe quantity Radix Salviae Miltiorrhizae total phenolic acids extract and starch and carboxymethyl starch sodium and adopt the equivalent method mix homogeneously that progressively increases, with an amount of PVP ethanol solution soft material processed, 14 mesh sieves are granulated, 50～60 ℃ of dryings 1 hour, the magnesium stearate that adds recipe quantity is with 14 mesh sieve granulate.
2 tablettings
Getting above-mentioned granule incapsulates.
Embodiment 8 freeze-dried powders
Prescription
Technology
Adjuvant mannitol in weighting raw materials Radix Salviae Miltiorrhizae total phenolic acids extract and the prescription adds injection water 1500ml, stirring and dissolving, 0.5 the gram activated carbon stirs decolouring 20 minutes, 0.45 micron microporous filter membrane decarburization, moisturizing to 2000 milliliter, aseptic filtration, packing, lyophilization, namely.
Claims (7)
1. a preparing salvianolic acids is characterized in that may further comprise the steps
(1) the moisture lower alcohol extraction of Radix Salviae Miltiorrhizae;
(2) polyamide or macroporous resin column are separated on the extracting solution;
Described lower alcohol is C
1～C
4Straight or branched saturated alkyl alcohol;
In the step (1), moisture lower alcohol weight percent concentration is 30-85%; Extracting method is selected from reflux, extract,, decoction, dipping, percolation and counter-current extraction;
In the step (2), also comprising polyamide column or macroporous resin column on the extracting solution, is the moisture lower alcohol I flushing of 20-35% with weight percent concentration, and the reuse weight percent concentration is the moisture lower alcohol II eluting of 50-80%, collects eluent, concentrates drying; For separation process together, moisture lower alcohol I concentration is less than moisture lower alcohol II.
2. the described preparation method of claim 1 is characterized in that,
Described lower alcohol is methanol, ethanol or isopropyl alcohol.
3. the described preparation method of claim 1 is characterized in that, described macroporous adsorbent resin is styrene type, and polyamide material is caprolactam.
4.
PowerProfit requires 1 described preparation method, it is characterized in that, step (2) is passed through ion exchange resin with extracting solution before upper prop separates.
5. with the Radix Salviae Miltiorrhizae total phenolic acids of any preparation method preparation of claim 1-4.
6. the described Radix Salviae Miltiorrhizae total phenolic acids of claim 5 is characterized in that, total phenolic content 〉=80% wherein, the content of salvianolic acid B wherein 〉=50%.
7. be active component with the described Radix Salviae Miltiorrhizae total phenolic acids of claim 5, said forms of pharmaceutical compositions on any pharmaceutics that the adding acceptable accessories is made.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200810152400 CN101721467B (en) | 2008-10-21 | 2008-10-21 | Method for preparing total salvianolic acid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200810152400 CN101721467B (en) | 2008-10-21 | 2008-10-21 | Method for preparing total salvianolic acid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101721467A CN101721467A (en) | 2010-06-09 |
| CN101721467B true CN101721467B (en) | 2013-08-21 |
Family
ID=42443418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200810152400 Active CN101721467B (en) | 2008-10-21 | 2008-10-21 | Method for preparing total salvianolic acid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101721467B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108126154A (en) * | 2017-12-29 | 2018-06-08 | 辽宁上药好护士药业（集团）有限公司 | A kind of preparation method and application for the nano dispersion fluid for treating obstruction of collaterals by blood stasis arthralgia-syndrome pain |
| CN108159108B (en) * | 2018-02-26 | 2021-08-10 | 辽宁昱众合医药科技有限公司 | Preparation of pithecellobium clypearia total phenolic acid and application of pithecellobium clypearia total phenolic acid in antibacterial and anti-inflammatory drugs |
| CN108904590A (en) * | 2018-08-15 | 2018-11-30 | 康美保宁（四川）制药有限公司 | The herbal paste method processed of Radix Salviae Miltiorrhizae in a kind of preparation process of Lemaiwan pill |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1887849A (en) * | 2006-07-13 | 2007-01-03 | 正大青春宝药业有限公司 | Salvianolic acid A preparing process |
-
2008
- 2008-10-21 CN CN 200810152400 patent/CN101721467B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1887849A (en) * | 2006-07-13 | 2007-01-03 | 正大青春宝药业有限公司 | Salvianolic acid A preparing process |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101721467A (en) | 2010-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI621443B (en) | Traditional Chinese medicine composition and its use, medicinal preparation containing the traditional Chinese medicine composition and compound salvia miltiorrhiza micro-droplet, and preparation method of the microdroplet | |
| EP3020408B1 (en) | Traditional chinese medicine composition, and preparation and application thereof | |
| WO2006034655A1 (en) | Steroidal saponin pharmaceutical composition, its preparation method and use | |
| WO2018058261A1 (en) | Traditional chinese medicine composition for treating psoriasis and preparation method thereof | |
| WO2005051404A1 (en) | Pharmaceutical composition for the treatment of cardiovascular and cerebrovascular diseases | |
| CN101073599A (en) | Total tanshinone and total phenolic acid extract in red-rooted salvia root and its production | |
| US20050159491A1 (en) | Preparation and application of transhintotalphenolic acid | |
| CN104415045A (en) | Pharmaceutical composition | |
| WO2008145064A1 (en) | The method for a sequoyitol-containing extract obtaining from the genus of trifolium, sobyean and ginkgo biloba and use thereof | |
| CN101721467B (en) | Method for preparing total salvianolic acid | |
| TWI417091B (en) | Anti-obesity agents and pharmaceuticals, foods or cosmetics that have a fat accumulation inhibitory effect | |
| KR100733764B1 (en) | Composition comprising the cortex extract of albizzia julibrissin or kuraridinol isolated therefrom for preventing or treating hyperlipidemia | |
| CN1679706A (en) | Medicinal preparation containing notoginseng and rhodiola root for cardio-cerebral blood vessel diseases and its preparing method | |
| CN105311085B (en) | Leaf or flower extract of honeysuckle stem or its base plant honeysuckle, its preparation method and application | |
| CN101721468B (en) | Method for preparing salvianolic acids | |
| CN100509009C (en) | Chinese medicinal preparation for treating heart cerebrovascular disease and ischemic apoplexia and making method thereof | |
| CN103028109B (en) | Traditional Chinese medicine agent for treating Alzheimer disease | |
| CN101974011B (en) | New compound methyl brevicate with medical activity | |
| CN101156882A (en) | Preparation method of pseudo-ginseng protopanoxadiol saponin and its uasage | |
| ZA200603160B (en) | Use of agomelatine in obtaining medicaments intended for the treatment of bipolar disorders | |
| CN105218495B (en) | A kind of red sage root water soluble ingredient noval chemical compound, preparation method and applications | |
| CN101974012B (en) | Novel compound ethyl brevicate with pharmaceutical activity | |
| CN104116753A (en) | Application of aucubin to preparation of medicines for treating idiopathic pulmonary fibrosis | |
| CN103989966B (en) | Medicine composition for preventing and treating migraine disease and preparation method and application thereof | |
| CN101974010B (en) | New compound erigeron breviscapus acid with officinal activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |